Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease

“…a certain number or velocity of new metastases. The generalizability of our results is also limited by the heterogeneity of our study population, particularly as the relatively small sample size hampers subgroup analysis of different primary tumors and OMD states: patients with repeat oligorecurrence at baseline might have a favorable prognosis [25] and thus benefit from repeat SBRT, albeit their systemic therapy-free interval was not significantly different from induced oligorecurrence patients in the present study (p = 0.10). The lack of a control group in our study also prohibits assumptions on whether the delay of systemic therapy might adversely affect OS, which should at best be addressed in a prospective, randomized setting.…”

ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases

“…These groups are further subdivided into oligorecurrence, oligoprogression and oligopersistence, depending on whether the patient is under systemic therapy and whether the lesions are progressing. The classification might have prognostic value [16] and is currently being validated in clinical trials, such as the prospective observational OligoCare trial (NCT03818503) [17]. For patients with bone metastases, the oligometastatic state is relevant and besides symptom palliation improved (progression free) survival might become a relevant treatment goal.…”

Oligometastasis in breast cancer—current status and treatment options from a radiation oncology perspective

“…Criteria for subclassification include timing of OMD (synchronous vs. metachronous), history of previous OMD (repeat vs. de novo OMD), systemic therapy at the time of OMD diagnosis (oligorecurrence vs. oligoprogression), response to systemic therapy (oligopersistence vs. oligoprogression), and previous history of polymetastatic disease (induced OMD). This classification was recently validated in a retrospective single-center cohort of 385 patients with OMD [ 13 ].…”